Pfizer Inc. (NYSE:PFE) has been persuading doctors in UK not to prescribe Generic Lyrica for treating pain and to support the company’s stance regarding a court ruling in UK which also declared recently that the physicians should refrain from prescribing the drug for the treatment of pain. The court’s decision came as a result of an ongoing conflict concerning the patent of the medicine.

The conflict was initiated last year in July when a patent was lost by Lyrica regarding the treatment of epilepsy and generalised anxiety problems. However, Lyrica can still do treatment for pains and the patent for that is valid through the year 2017. The expiration of the patent regarding the two above mentioned conditions has given an indication to the drug makers who are concerned with the making of the generic versions of the medicine.

Pfizer (NYSE:PFE) has been busy dealing with the legal challenges which emerge due to these generic versions which are speculated to reduce the sales of the original medicine by offering their cheaper prices. A trial is due in June 2015 which will be addressing one similar challenge.

Pfizer (NYSE:PFE) came up with a letter last year which was not addressed to any of the doctors nor was it addressed to the pharmacies; the letter was meant for the Clinical Commission Group (CCGs) and was meant to be a warning for them to stop prescription of generic Lyrica for the treatment of pain.

CCGs are organizations in the UK which are administered by the UK based National Health Service. These organizations comprise of local doctors who have various responsibilities and amongst those responsibilities is the decision of prescribing drugs to the patients.

Although Pfizer (NYSE:PFE) issued the letter, it was not mentioned in the letter as to how the company plans on enforcing the warning or what action the company will take if the doctors do not abide by the warning. Pfizer (NYSE:PFE), while discussing the patent matter with the NHS as well as the Department of Health said that the move was not a clinical matter but was more of a legal matter.

The company further explained its apprehensions and said that the doctors might just prescribe the generic version of the drug for pain treatment. On the other hand, the Department of Health recommended that the company should get in touch with the CCGs instead.

Many doctors were not thrilled about the warnings which were forwarded by Pfizer (NYSE:PFE). An organization called The Royal College of Physicians which represents around 20,000 doctors declared that Lyrica has been an effective drug and has benefited a lot of patients. The organization said that the warning issued by Pfizer (NYSE:PFE) will just deprive the patients from getting access to an effective drug.

However, a British High Court judge Richard Arnold who had been handling the patent ruled the NHS against supporting the usage of Lyrica and also asked the organization to communicate with the doctors.

A statement was released by NHS which indicated that the agency just wants the practitioners to be aware of the guidelines set by CCGs prior to prescribing the drugs for pain treatments. Pfizer (NYSE:PFE) made it clear that the company has no intention of taking any legal action against any organization or individual regarding this matter.

Amgen Inc. (NASDAQ:AMGN) has appealed against the court’s refusal to pass orders against the launch of Zarxio,developed by Sandoz Inc.,  which  happens to be the biosimilar version of Neupogen, Amgen Inc. (NASDAQ:AMGN)has filed an appeal both against the rejection of its petition and the court’s decision which favored Sandoz Inc.

Aude Gerspacher and Asthika Goonewardene, who have been serving as analysts at Bloomberg presented a report. This report reflected the court’s decision whereby the request of both the companies for acceleration of the case was granted. Sandoz Inc.’s response is due at 31^st of March, whilst Amgen Inc. (NASDAQ:AMGN) would be making its reply by the second of April. The court’s ensuing decision about Amgen Inc. (NASDAQ:AMGN)motion would probably come forward in early April.

This second petition filed by Amgen Inc. (NASDAQ:AMGN) against court’s decision in favor of Sandoz Inc. as well as its denial of the former company’s petition will cause a further delay in the release of biosimilar drugs in US. Even though, Zarxio has been approved by US Food and Drug Administration and the court has also given its decision in favor of it, still the launch of Zarxio will probably undergo a delay.

There are no legal restrictions or obstacles hindering this launch. However, SandozInc. has agreed to withhold this launch until the eleventh of May or until the court gives its decision in favor of Sandoz Inc., against the second petition filed by Amgen Inc.(NASDAQ:AMGN).

Following the manufacture of Zarxio, Sandoz Inc. had to face a petition filed against it by Amgen Inc. (NASDAQ:AMGN).The allegation placed by the latter company was primarily unfair competition along with patent infringement. This is because, Zarxio is a biosimilar version of Amgen Inc.’s(NASDAQ:AMGN) block buster drug Neupogen. Neupogen is basically deployed for the treatment of cancer patients, in order to cure Neutropenia. Another allegation placed by Amgen Inc.(NASDAQ:AMGN) on Sandoz Inc. was that it hasn’t complied with the disclosure regulations, as required by the Biologics Price Competition and Innovation Act (BPCIA).

Zarxio had been developed from the same active ingredient which makes up Neupogen. An application for the approval of this drug was filed with the US Food and Drug Administration in July 2014. This was the first biosimilar drug brought forward for approval. Previously FDA did not undertake the approval of such drugs because of the unavailability of an appropriate framework in order to establish the efficacy and safety of these drugs.

Patient Protection and Affordable Care Act 2010 gave authority to FDA and all such bodies to examine such imitation drugs and ultimately approve or disapprove them. Since these imitation drugs aren’t the exact copies, therefore their examinations also has to be very comprehensive.

According to firm the documentary created a random stir, without in actuality giving any new or different proof. Wunderlich clearly stated that the investigative report appealed the public on an emotional level rather giving them solid facts and figures. Blake Harper who is an analyst at the security firm, went on the record to say that the trailer of the documentation does not offer any new and revealing facts about Yelp Incorporation(NYSE:YELP).

The content of the documentary that revolves around Yelp’s (NYSE:YELP)review filter. All the various demeaning and influencing feedback related to the controversies was not proved by the courts, the FTC as well as the Harvard Business School studies; no concluding proof has been provided. He added further to his statement that according to the Quantcast data reports, Yelp (NYSE:YELP)is slowly growing and making its mark, which is proved in the numbers that appeared in the first quarter.

He accredited and approved the fact that companies all over the world behave extremely delicate and emotive when it comes to explaining negative feelings towards them. Same is the scenario with Yelp(NYSE:YELP), it has also its fair share of controversial and adverse feedback; but according to Mr. Harper, Yelp (NYSE:YELP)is not part of any grand scheme of dishonesty or treachery. Yelp (NYSE:YELP)was founded in 2004 and has supported all those who are interested in local businesses like dentists, hair stylists, home industries and mechanics.

Since then the number of people who have come to get aid from the organization has tremendously increased as reported in the first quarter of the year 2015. Wunderlich has predicted that the company will continue to move forward and show positive growth in between 8-10%. Positive feedback is also being given about the amount of investors and the marketing strategy that is being opted by Yelp (NYSE:YELP)in the coming years. The organization is set to believe Yelp (NYSE:YELP)has a strong customer following and has enough finances to sustain its business.

While Wunderlich as a firm strongly supports Yelp (NYSE:YELP)and believes in the future of the company, Wall Street on the other hand is going all out in showing not only its disinterest but also indifferent behavior towards Yelp(NYSE:YELP). Market analysts however have given positive feedback, out of total of 39 analysts 25 highly recommend in buying the stocks of the company while 13 state that it is better to hold off for now. The target price issued by analysts to the stock of Yelp is $66.23.

The company is involved in the business of lending loan to small American businesses. Company’s recent ride in terms of its share price was because of over rating of the shares by a couple of analysts. The shares otherwise were worth no more than $15.75/share. The company did not grow as much as it was anticipated, which explains the rise and fall in the stock price.

Looking at the company otherwise reveals that financial situation of the company has never been very impressive. OnDeck Capital (NYSE:ONDK) has been the last option for the borrower and most of its customers have been high-risk borrowers. Due to this situation many borrowers default in the loans which result in losses that weigh heavily on the shares of the company.

Company’s annual report shows a static pool when it comes to company’s loan performance. Static pool is one entity that holds the power to impact the growth of loans on credit metrics. Static pool means that the growth of the lender is fast due to which the performance of the new loans seems dwarf. Thus, this effect contributes to an overall slower growth of the company and takes quite some time to develop.

Though company’s annual report shows great revenue generation from the loans, it can be seen that a major chunk of OnDeck Capital’s (NYSE:ONDK) earnings goes into paying back its previous loans. This refinancing of balances seems quite problematic. Moreover, repeated financing of the borrowers, who are already in debt, is also another major issue. This situation leads to many loan defaults that the company has to bear, as many borrowers are not able to pay back the loan which leads them to borrowing more loan and shows how badly they are stuck in this cyclic process.

Moreover, the consumer protections and usury laws on interest rates, does not apply to businesses and are applicable to people only. Due to this the company cannot get personal guarantees on the loans it lends.

Furthermore, the recent trend in online lending is also gaining popularity. This is also reducing company’s current business as these online lenders do not look at borrower’s current position and grant loans on the basis of the borrower’s future prospect. To improve its situation OnDeck Capital (NYSE:ONDK) can trek on the same path and start online lending however, it will have to do a cost-benefit analysis first.

However, not all hope is lost. Investors just have to understand that many risks that the company incurs are binary. In many cases, lending to small businesses earns the company good profits though some defaults are bound to occur.

There has not been any major change in the OnDeck Capital (NYSE:ONDK) since it released its IPO. For the time being by looking at the reports analysts and investors are just revising their predictions and expectations. Thus, there is not much to lose than to gain.

Besides this giant loss, the company has made it possible to give a free cash flow for the whole year of approximately $57 million. Free cash flows describe the original amount earned by the organization so it is of more value than the total payment.

Due to the supply of weak standard of measurements for health check of business, and a few insupportable tasks, J.C. Penny Co. Inc. (NYSE:JCP) was able to give free cash flows. These free cash flows are extremely dependent on the net earnings of the company.

Three basic things are counted that amplified the company’s free cash flows. It gives a huge amount of $70 million for the sales of functioning property as determined by the free cash flows, which is a single-time thing. If this amount is excluded, the free flows become negative. Secondly, a conference call was conducted about a year before, which revealed an amount of $250 million in capital expenses. Chief Financial Officer of J.C. Penny Co. Inc. (NYSE:JCP) remarked about the company surviving on diet for a short time. According to another calculation it was found that the company had spent more than $950 million on capital expenses, two years ago.

J.C. Penny Co. Inc. (NYSE:JCP) has to preserve a specific level of CAPEX to maintain the company’s assets, where the company is spending well below that level. Expended CAPEX amount by J.C. Penny Co. Inc. (NYSE:JCP) was $300 million yearly, which improved free cash flows, but this improvement is not for a longer time.

Moreover, benefit caused by the alteration in working was $379 million, which was the result of J.C. Penny Co. Inc. (NYSE:JCP) decreasing its inventory levels as compared to the previous year. This move increased the working capital and free cash flow, but this optimization is not possible to happen each year, since when the company wants to expand its sales.

Practicing these scenarios can surely affect the health conditions of the company, as this adjusted free cash flow gives a rough estimate about its position.  Since J.C. Penny Co. Inc. (NYSE:JCP) reported a positive free cash flow, it doesn’t mean that the company is making profits and is going strong, it is still far behind. It’s ironic that the company was unable to make profits even during a holiday quarter.

J.C. Penny Co. Inc. (NYSE:JCP) will be working for free cash flows even this year, again through under spending of capital expenditure, along with the expended gains from working capital. Sales are definitely going to be uplifted with improved business strategies. Apart from all these plans, company would still have to wait for several years to earn a considerable profit.

This generic drug of Sovaldi, developed by Incepta Pharmaceuticals Ltd. goes by the name of Hopetavir and will be sold at $900 for a period of 12 weeks. On the other hand, Gilead Sciences Inc.’s (NASDAQ:GILD) Sovaldi tended to be very expensive. Up till now, it was the most effective drug for hepatitis C treatment and was being sold at $86,000 for a period of twelve weeks. Owing to this reason, Gilead Sciences Inc. (NASDAQ:GILD) had to face a lot of criticism, regarding the overpricing of its drugs. Another drug manufactured by Gilead Sciences Inc. (NASDAQ:GILD) of the like kind, Harvoni, comes with an even higher price tag of $94,500 for 12 weeks.

The hefty prices of these drugs makes them unaffordable. Quite a large of number of people are suffering from Hepatitis C, particularly in developing countries, and such expensive treatments are out of question for them. Therefore, there was a dire need for a generic version of this drug; so that people who cannot afford such highly priced drugs can still have access to hepatitis treatment.

Since Gilead Sciences Inc. (NASDAQ:GILD) has been coming across a lot of criticism regarding the high rates of its drugs, therefore recently it has been striving to make its drugs a little reasonable, so that they can be afforded in the less economically privileged countries

In accordance with these efforts, Gilead Sciences Inc. (NASDAQ:GILD) has been making quite a number of deals with drug manufacturing companies in India, allowing these companies to come up with cheaper and generic versions of Sovaldi. These low-cost HCV drugs are being manufactured for 91 developing and under developed countries of the world.

Statistics suggest that approximately 150 million people in the world are suffering from Hepatitis C. From this 150 million, a large proportion of affected people belong to either developing or under developed countries. Of the total population that makes up the hepatitis patients, more than half i.e. approximately 73% of the patients come from low-income countries. This data has been brought forward by Doctors without Borders.

A recent deal was finalized between Gilead Sciences Inc. (NASDAQ:GILD) and Natco Pharma Ltd. (BOM:524816) for the production of generic versions of Sovaldi in Nepal. In context of this deal, a statement was made by Hitesh Mahida, who happens to work as an analyst at Antique Stock Broking. Mahida said that even though the competition between the manufacturing of these generic drugs is going to be intense; however the market is very wide to welcome all these versions.

Although, Gilead Sciences Inc. (NASDAQ:GILD) has been giving licenses to many pharmaceutical companies for the production of generic versions of its block buster HCV drug, Sovaldi; yet, Incepta Pharmaceuticals Ltd. did not seek any such license from Gilead Sciences Inc. (NASDAQ:GILD). A major reason for this is that the latter company belongs to Bangladesh, and Bangladesh is alleviated from all patent protection rules, being a very non-developed country, according to the WTO treaty.